logo

For the Inventor, By the Inventor

San Diego, CA, United States of America

Zhi-Liang Chu

This inventor holds 18 USPTO granted patents and 7 published patent applications and 3 EPO patents, primarily in Pharmaceutical Compositions. Top assignees: Arena Pharmaceuticals, Inc., The Burnham Institute. Active years: 2005-2015.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Zhi-Liang Chu. Retrieved from https://idiyas.com/inventor/zhi-liang-chu

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 18 

 

Average Co-Inventor Count = 2.9

ph-index = 3

Forward Citations = 38(Granted Patents)


Company Filing History:

goldMedal17 out of 218 
 
Arena Pharmaceuticals, Inc.
 patents
silverMedal1 out of 94 
 
The Burnham Institute
 patents

Years Active: 2005-2015

Loading Chart...
Loading Chart...
Areas of Expertise:
GLP-1 Secretagogue
GPR119 Agonists
Diabetes Treatment
Bone Mass Increase
Combination Therapy
Pharmaceutical Compositions
Peptide YY
Osteoporosis Treatment
Glucose-Dependent Insulinotropic
Nucleic Acid Molecule
G Protein-Coupled Receptor
PANG6 Polypeptide
18 patents (USPTO):Explore Patents
1. 9182414 - Methods for identifying a GLP-1 secretagogue (2015-11-10),
2. 8883714 - Pharmaceutical compositions comprising GPR119 agonists which act as peptide YY (PYY) secretagogues (2014-11-11),
3. 8580526 - Methods of using GPR119 receptor to identify compounds which stimulate glucose-dependent insulinotropic peptide secretion (2013-11-12),
4. 8486646 - Methods of using a G protein-coupled receptor to identify peptide YY (PYY) secretagogues (2013-07-16),
5. 8198232 - Combination therapy for the treatment of diabetes and conditions related thereto and for the treatment of conditions ameliorated by increasing a blood GLP-1 level (2012-06-12),
6. 8101626 - GPR119 receptor agonists in methods of increasing bone mass and of treating osteoporosis and other conditions characterized by low bone mass, and combination therapy relating thereto (2012-01-24),
7. 8030270 - Methods for identifying GLP-1 secretagogues (2011-10-04),
8. 8026212 - Methods of preparing pharmaceutical compositions comprising GPR119 agonists having the effect of glucose-dependent insulinotropic peptide secretatgogues (2011-09-27),
9. 8026074 - Methods of using GPR119 to identify compounds useful for increasing bone mass in an individual (2011-09-27),
10. 8022034 - Combination therapy for the treatment of diabetes and conditions related thereto and for the treatment of conditions ameliorated by increasing a blood GLP-1 level (2011-09-20),
11. 8017574 - Methods of preparing pharmaceutical compositions comprising GPR119 agonists having the effect of glucose-dependent insulinotropic peptide secretagogues (2011-09-13),
12. 8003597 - Combination therapy for the treatment of diabetes and conditions related thereto and for the treatment of conditions ameliorated by increasing a blood GLP-1 level (2011-08-23),
13. 7838254 - Methods of using GPR119 to identify peptide YY (PYY) secretagogues and compounds useful in the treatment of conditions modulated by PYY (2010-11-23),
14. 7833730 - Methods of using GPR119 to identify compounds useful for increasing bone mass in an individual (2010-11-16),
15. 7816364 - GRP119 receptor agonists in methods of increasing bone mass and of treating osteoporosis and other conditions characterized by low bone mass, and combination therapy relating thereto (2010-10-19),

Title: The Innovative Contributions of Zhi-Liang Chu

Introduction

Zhi-Liang Chu, based in San Diego, California, is a prominent inventor known for his significant contributions to the field of medical innovations. With an impressive portfolio of 18 patents, Chu has focused his research on advancements that target metabolic disorders and obesity through innovative pharmaceutical compositions and methodologies.

Latest Patents

Among his latest inventions is a patent for "Methods for identifying a GLP-1 secretagogue." This invention presents a novel combination of a BRS-3 agonist and a dipeptidyl peptidase IV (DPP-IV) inhibitor aimed at lowering blood glucose levels and increasing blood GLP-1 levels. This innovative approach holds potential for treating or preventing obesity and diabetes, as well as related health conditions. Additionally, he has developed a patent concerning "Pharmaceutical compositions comprising GPR119 agonists which act as peptide YY (PYY) secretagogues." This work focuses on utilizing the GPR119 receptor to identify compounds that can stimulate PYY secretion, proving useful in treating a range of disorders such as bone-related conditions, metabolic disorders, and cancers.

Career Highlights

Zhi-Liang Chu has had a notable career, with his work spanning various esteemed organizations. He has made significant contributions during his tenure at Arena Pharmaceuticals, Inc. and The Burnham Institute, where he has been instrumental in pushing the boundaries of medical research. His innovative approach to understanding and treating conditions related to metabolic health has made him a respected figure in his field.

Collaborations

Throughout his career, Chu has collaborated with distinguished colleagues such as James N. Leonard and Robert M. Jones. These partnerships have helped foster a creative environment that enhances the development of groundbreaking inventions aimed at improving patient health outcomes.

Conclusion

Zhi-Liang Chu’s innovative spirit and dedication to research have led to substantial advancements in the medical field, particularly in the treatment of obesity and metabolic disorders. His contributions to pharmaceuticals through patented inventions not only highlight his exceptional skills as an inventor but also promise a positive impact on future health solutions. As he continues to explore new horizons in innovation, Zhi-Liang Chu remains a key figure in shaping the landscape of medical research.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…